(Reuters) – The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for four COVID-19 treatments, including those from Eli Lilly (NYSE:LLY) and Regeneron (NASDAQ:REGN).
(This story has been corrected to say four treatments, not five, in the headline and paragraph 1)
This post appeared first on investing.com
